API | delafloxacin meglumine

delafloxacin meglumine (baxdela) Report issue

Small molecule Approved ^FDA Fast Track ^FDA Priority Review ^FDA

Drugs@FDA

Active Ingredient History

NOW

Delafloxacin sold under the brand name Baxdela among others, is a fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections. ^Wikipedia

Chemistry

SMILES: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F
InChIKey: AHJGUEMIZPMAMR-WZTVWXICSA-N
Mol. Mass: 635.98
ALogP: 1.92 Partition coefficient
ChEMBL Molecule:
delafloxacin meglumine

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA gyrase subunit A (Escherichia coli K-12) ^UniProt
- DNA gyrase subunit B (Escherichia coli K-12) ^UniProt
- DNA topoisomerase 4 subunit A (Escherichia coli K-12) ^UniProt
- DNA topoisomerase 4 subunit B (Escherichia coli K-12) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral, Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$28.7505 - $605.0100

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

delafloxacin meglumine

Organizations (1)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Skin Diseases, Bacterial

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue